Role of high-dose therapy in diffuse large B-cell lymphoma

Annals of Oncology

Volumn 11, Issue SUPPL. 3, 2000, Pages 117-121

  Cerny, Thomas ^a   Betticher, Daniel ^b  

^a Department of Oncology/Haematology ^*  (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINBLASTINE; VINCRISTINE; VINDESINE;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG MEGADOSE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033770599     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_3.117     Document Type: Conference Paper

References (33)

1. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma
2. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin's lymphoma
4. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamidetreated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor
5. Granulocytemacrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
6. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
7. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies
8. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow trenaplantation in lymphoma patients
9. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma
10. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen
11. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation
12. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma
13. High-dose carmustine, etoposide and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma
14. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
15. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to firstline CHOP
16. A EBMT survey of 671 cases submitted to autologous stem cell transplantation for diffuse large B cell Lymphoma
17. A predictive model for aggressive non-Hodgkin's lymphoma
18. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
19. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
20. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation
21. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study
22. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission
23. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma
24. Autologous bone marrow transplantation in poor prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study
25. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma
26. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
27. Failure of inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH93-3 study
28. High dose chemotherapy with autologous stem cell transplantation in high grade NHL: First analysis of a randomized multicenter study
29. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma Cooperative Study group
30. High dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery?
31. Prospective randomised comparison of MACOP-B vs. rhGM-CSF-supported highdose sequential myeloablative chemoradiotherapy in diffuse large cell lymphomas
32. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
33. International Consensus Conference on high-dose therapy with hematopoieric stem-cell transplantation in aggressive non-Hodgkin's Lymphomas: Report of the jury